The Peptide NewsroomPeptide research, industry and supply-chain headlines

Advertorial Review Lists Synthesis Peptides GHK-Cu at $36.99, But Its COA Went Unverified

Topic card: GHK-Cu celebrity

A paid advertorial published through Newswire on October 3, 2026 examines Synthesis Peptides' advertised GHK-Cu pricing, its volume discounts, and a single supplier-linked Certificate of Analysis. The piece discloses up front that it is promotional, that a commission is earned on purchases made through its links, and that no product was bought or tested.

GHK-Cu is a copper-binding tripeptide sold widely into the research-chemical market. Synthesis Peptides describes itself as a veteran-owned, U.S.-based supplier and lists a Las Vegas contact address, though the review notes the pages it read do not name a legal entity, a founder, or a founding year.

The numbers on the page

On October 3, 2026, the GHK-Cu listing advertised $36.99 for one unit, with 5%, 15%, and 20% off at three, five, and ten units, according to the brand. The review calls those advertised figures rather than checkout totals, since no cart was tested and taxes, package protection, or membership pricing could change the final amount.

The catalog page listed 43 products as of that date. Pricing for the rest of the catalog was not reviewed.

One certificate, not authenticated

The certificate linked from the GHK-Cu listing, report KVR-2026-18E956-S187 for lot GHK50626 dated 05/29/2026, prints a batch-average purity of 99.678% and net content of 49.30 mg against a labeled 50 mg, with LC-MS identity and an endotoxin criterion marked PASS. The review says it read that document as printed and did not authenticate it with the named issuing laboratory, which showed no address or separate analysis date on the report.

That distinction is the most useful thing in the piece. A readable PDF on a product page and a confirmed analysis from an accredited lab are different objects, and the review refuses to collapse them.

Where the brand's own pages disagree

The homepage advertises COAs on every batch while the Terms and Conditions describe them as available upon request. The reporting window for a defective or incorrect order is 48 hours on the homepage FAQ and 72 hours on the Shipping and Returns page, and shipment protection is described as included in one place and an optional checkout add-on in another.

Bottom line

The review reaches no verdict on legitimacy, and says plainly that a working storefront is not a confirmed legal entity and an unauthenticated certificate is not a verified one. Coming from a commissioned advertorial, that restraint is more than the format usually offers, and it leaves the verification work exactly where it started.

Source: RSS.app — Peptides bundle. Read the original.

Filed under: celebrity

Comments (0)

Discussion happens on Reddit.
Questions and corrections go to r/PeptideNewsroom.

Go to r/PeptideNewsroom

Corrections are the most useful thing you can post. Comments touching dosing, sourcing or links are held for a moderator first.

More from The Peptide Newsroom

Gray Market Peptide Users Report Months of Side Effects, and the Research Is Thin

KFF Health News, written up by Futurism, reports on users of research-grade BPC-157 who describe fatigue, spasms and migraines lasting months after a few days of use. A former FDA official quoted in the piece says robust human studies on these compounds remain rare.

NextWave Peptides Launches U.S. Catalog Promising Lot-Matched COAs, But the Records Stay In-House

NextWave Peptides has announced a U.S.-based research peptide catalog organized around a lot-matched COA library and a stated 99%+ purity standard. The announcement is a company press release, and it does not name the third-party lab or say how much of the catalog the documentation covers.

Sponsored Explainer Casts Thymosin Alpha-1 as a Signaling Molecule, Then Points to a Vendor

A sponsored explainer on Whig.com surveys proposed roles for Thymosin Alpha-1 in immune signaling, stress response and antigen presentation, then closes by pointing readers to a vendor. Every claim in the body is hedged, and no trial size or outcome figure appears anywhere in the piece.